ERBB2 and neoplasm: These frequently included key oncogenes, such as MYC, the tyrosine-protein kinase ABL, and human epidermal growth factor receptor 2 (HER2/neu), which contribute to tumor-specific genomic imbalances that may drive cancer progression [18].